{"id":"W4379523514","doi":"10.1136/annrheumdis-2023-eular.2415","title":"POS0826 SAFETY PROFILE OF UPADACITINIB UP TO 6.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS","year":2023,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval","funders":"Chugai Pharmaceutical; Samsung; Genentech; Medac; H. Lundbeck A/S; Eisai; Astellas Pharma; Mylan; Gigtforeningen; Eli Lilly and Company; AstraZeneca; Kræftens Bekæmpelse; Daiichi-Sankyo; Teva Pharmaceutical Industries; Celgene; Biogen; Gilead Sciences; Kowa Company; Sanofi; Amgen; Pfizer","keywords":"Medicine; Adverse effect; Discontinuation; Internal medicine; Adalimumab; Rheumatoid arthritis; MedDRA; Population; Clinical trial; Pharmacovigilance","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000285412,0.0001141728,0.0004649466,0.0001205474,0.00002840526,0.000003005393,0.0002849457,0.00008018749,0.0002597871],"category_scores_gemma":[0.000590479,0.00007557563,0.00013782,0.0005060806,0.0002531071,0.00004051395,0.0001338405,0.00007455363,0.00001925028],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000004045147,"about_ca_system_score_gemma":0.00005404799,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005267722,"about_ca_topic_score_gemma":0.00001177019,"domain_scores_codex":[0.9987569,0.0002171168,0.0005348189,0.0001565261,0.0001056802,0.000228912],"domain_scores_gemma":[0.9989417,0.0002935725,0.0002403117,0.000355756,0.000135105,0.00003360597],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004254153,0.001798911,0.6130694,0.0009458349,0.001072521,0.000002749123,0.002405328,0.0001367889,0.001927519,0.002293472,0.02550794,0.3465854],"study_design_scores_gemma":[0.001277492,0.0004131664,0.9863628,0.001351648,0.00001852739,5.235273e-7,0.0002921578,0.000003301801,0.00935986,0.0004679039,0.0003452548,0.0001074323],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997466,0.0007657376,0.000007940631,0.0003942685,0.0001414997,0.0003750049,0.0007337327,0.00001426658,0.000101598],"genre_scores_gemma":[0.9990938,0.0004325252,0.0001108213,0.00008757108,0.000001475888,0.00001228788,0.00003537662,0.00001064072,0.0002155009],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3732933,"threshold_uncertainty_score":0.3081885,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02175560958648856,"score_gpt":0.2787929088595743,"score_spread":0.2570372992730857,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}